ArticleJournal of surgical case reports2025
Inflammatory optic neuritis and scleritis following commencement of semaglutide: a case report.
Article in Journal of surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the documented increased risk of non-arteritic ischaemic optic neuropathy (NAION), the widespread use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has raised concerns regarding their ophthalmic safety. This study presents a unique case of inflammatory optic neuritis and scleritis in a 43-year-old female one month following commencement of semaglutide. Extensive investigations for underlying systemic causes, including autoimmune and connective tissue disorders were negative. Treatment with systemic corticosteroids led to a gradual resolution of symptoms and return of vision to baseline over a three-month period. This case highlights a potential link between semaglutide and inflammatory ocular conditions. Clinicians should maintain an open mind when evaluating optic neuropathies in the context of GLP-1 RA use and consider corticosteroid-responsive inflammatory aetiologies as alternatives to NAION. Multicentre population-based cohort studies are warranted to determine whether a true association exists and to elucidate the potential mechanisms underlying semaglutide-associated ocular inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.